Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama City, Okayama 700-8558, Japan.
Osteoarthritis Cartilage. 2013 Jan;21(1):165-74. doi: 10.1016/j.joca.2012.09.003. Epub 2012 Sep 24.
To investigate the inhibitory effects and the regulatory mechanisms of histone deacetylase (HDAC) inhibitors on mechanical stress-induced gene expression of runt-related transcription factor (RUNX)-2 and adisintegrin and metalloproteinase with thrombospondin motif (ADAMTS)-5 in human chondrocytes.
Human chondrocytes were seeded in stretch chambers at a concentration of 5 × 10(4)cells/chamber. Cells were pre-incubated with or without HDAC inhibitors (MS-275 or trichostatin A; TSA) for 12h, followed by uniaxial cyclic tensile strain (CTS) (0.5Hz, 10% elongation), which was applied for 30 min using the ST-140-10 system (STREX, Osaka, Japan). Total RNA was extracted and the expression of RUNX-2, ADAMTS-5, matrix metalloproteinase (MMP)-3, and MMP-13 at the mRNA and protein levels were examined by real-time polymerase chain reaction (PCR) and immunocytochemistry, respectively. The activation of diverse mitogen-activated protein kinase (MAPK) pathways with or without HDAC inhibitors during CTS was examined by western blotting.
HDAC inhibitors (TSA: 10 nM, MS-275: 100 nM) suppressed CTS-induced expression of RUNX-2, ADAMTS-5, and MMP-3 at both the mRNA and protein levels within 1h. CTS-induced activation of p38 MAPK (p38), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK) MAPKs was downregulated by both HDAC inhibitors.
The CTS-induced expression of RUNX-2 and ADAMTS-5 was suppressed by HDAC inhibitors via the inhibition of the MAPK pathway activation in human chondrocytes. The results of the current study suggested a novel therapeutic role for HDAC inhibitors against degenerative joint disease such as osteoarthritis.
研究组蛋白去乙酰化酶(HDAC)抑制剂对机械应力诱导的人类软骨细胞中 runt 相关转录因子(RUNX)-2 和解整合素金属蛋白酶与凝血酶敏感蛋白 5(ADAMTS)-5 基因表达的抑制作用及其调控机制。
将人类软骨细胞以 5×10(4)个/腔的浓度接种于拉伸室中。细胞用或不用 HDAC 抑制剂(MS-275 或曲古抑菌素 A;TSA)预孵育 12h,然后使用 ST-140-10 系统(STREX,日本大阪)施加单轴循环拉伸应变(CTS)(0.5Hz,10%伸长),持续 30min。通过实时聚合酶链反应(PCR)和免疫细胞化学分别提取总 RNA,并检测 RUNX-2、ADAMTS-5、基质金属蛋白酶(MMP)-3 和 MMP-13 的 mRNA 和蛋白水平表达。通过 Western 印迹检测 CTS 过程中不同丝裂原活化蛋白激酶(MAPK)通路的激活情况,以及是否存在 HDAC 抑制剂。
HDAC 抑制剂(TSA:10 nM,MS-275:100 nM)在 1h 内抑制 CTS 诱导的 RUNX-2、ADAMTS-5 和 MMP-3 的 mRNA 和蛋白水平表达。两种 HDAC 抑制剂均下调 CTS 诱导的 p38 MAPK(p38)、细胞外信号调节激酶(ERK)和 c-Jun N 末端激酶(JNK)MAPK 的激活。
HDAC 抑制剂通过抑制 MAPK 通路的激活抑制 CTS 诱导的人类软骨细胞中 RUNX-2 和 ADAMTS-5 的表达。本研究结果提示 HDAC 抑制剂在治疗骨关节炎等退行性关节疾病方面具有新的治疗作用。